Evidence map›Paper›PMID 26264150›Full record

ReviewTargeted oncology2016

Vemurafenib-induced progression of breast cancer: a case report and review of the literature.

Aleksei V Novik, Svetlana A Protsenko, Irina A Baldueva, Aleksander O Ivantsov, Tatyana L Nekhaeva, Zinaida Y Akhaeva, Grigoriy A Yanus, Aglaya G Iyevleva, Evgeny N Imyanitov

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Targeted oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Systemic Treatment of Metastatic Conjunctival Melanoma.Case reports in oncological medicine · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Aleksei V NovikN.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia. anovik@list.ru.
Svetlana A ProtsenkoN.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Irina A BalduevaN.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Aleksander O IvantsovN.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Tatyana L NekhaevaN.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Zinaida Y AkhaevaN.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Grigoriy A YanusN.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Aglaya G IyevlevaN.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Evgeny N ImyanitovN.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Institute of Oncology NN Petrov · RUNorth-Western State Medical University named after I.I. Mechnikov · RUSaint Petersburg State Pediatric Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild-type malignancies remains insufficiently studied. We observed a patient, who was administered vemurafenib for BRAF mutation-containing melanoma, but experienced immediate relapse of previously controlled breast cancer disease. Interestingly, breast cancer lesions underwent regression soon after vemurafenib discontinuation. Therefore, caution must be taken while considering vemurafenib treatment for patients with multiple tumors.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCarcinoma, Squamous CellDisease ProgressionFemaleHumansIndolesMelanomaMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSulfonamidesVemurafenibAntineoplastic AgentsBRAF protein, humanIndolesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSulfonamidesVemurafenib

Identifiers

PMID26264150
OpenAlexW1179364797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.